A Review of Pulmonary Arterial Hypertension Treatment in Extracorporeal Membrane Oxygenation: A Case Series of Adult Patients.
Heather TorbicBenjamin HohlfelderSudhir KrishnanAdriano R TonelliPublished in: Journal of cardiovascular pharmacology and therapeutics (2022)
The treatment of critically ill PAH patients is challenging given a variety of factors that could affect PAH drug concentrations. In particular, PAH patients on prostacyclin analogues placed on VA ECMO appear to have pronounced systemic vasodilation requiring vasopressors which is alleviated by temporarily reducing the intravenous prostacyclin dose. Patients should be closely monitored for potential need for rapid titrations in prostacyclin therapy to maintain hemodynamic stability.
Keyphrases
- pulmonary arterial hypertension
- end stage renal disease
- extracorporeal membrane oxygenation
- chronic kidney disease
- newly diagnosed
- ejection fraction
- prognostic factors
- pulmonary artery
- mesenchymal stem cells
- patient reported outcomes
- high dose
- molecular docking
- climate change
- bone marrow
- respiratory failure
- risk assessment
- molecular dynamics simulations
- quantum dots
- mechanical ventilation